ARS Pharmaceuticals’ neffy 1mg Secures the US FDA’s Approval to Treat Type I Allergic Reactions in Children
Shots:
- The US FDA has approved neffy 1mg (epinephrine nasal spray) to treat type I allergic reactions (incl. anaphylaxis) in children [≥4yrs. & 15-30kg (33-66lbs)]; commercially available in the US by end of May’25
- Approval was based on extensive clinical data with PK/PD results comparable to approved epinephrine injections in both pediatric & adult pts. Human factor studies showed that 10yr. old children along with untrained individuals can effectively administer neffy by following instructions
- Neffy nasal spray provides needle-free & easy-to-use approach for the treatment of severe allergies with 24mos. shelf life at room temperature & tolerance up to 122°F (50°C) for ~3mos.
Ref: Globenewswire | Image: ARS Pharmaceuticals
Related News:- ARS Pharmaceuticals Reports the EC’s Approval of Eurneffy (Adrenaline Nasal Spray) to Treat Type I Allergic Reactions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
